Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN Poll

 More »
Jan 30, 2012

California Biopharma Forecast

What is your forecast over the next 12 months for startup biopharma companies trying to do business in California?

Sunny
 
  19.3%
Cloudy
 
  33.7%
Stormy
 
  36.1%
Undecided
 
  10.8%

Suggest a Poll
More Polls » View Results »

California may still be called the Golden State, but its image among biotech and pharma startups has been tarnished. The financial squeeze has dried up sources of funding, plus the combination of federal and state red tape serves as a one-two punch. Nearly three-quarters (74.2%) of some 100 CEOs surveyed recently said their companies were forced to delay a research or development project in the last year. When asked why, more than two-thirds cited either lack of available financing, heavy-handed regulation, or both. As a result, some CEOs are looking at expanding overseas. How do you think California will fair?

Related Content

GEN News Highlights

MORE RELATED GEN NEWS HIGHLIGHTS

Insight & Intelligence™

MORE RELATED INSIGHT & INTELLIGENCE™

GEN Articles

MORE RELATED GEN ARTICLES

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll